HRAS - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
SMAD4	SMAD family member 4	Signaling by NODAL Signaling by Activin Signaling by BMP TGF-beta receptor signaling activates SMADs Downregulation of SMAD2/3:SMAD4 transcriptional activity Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription SMAD4 MH2 Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Transcriptional regulation of pluripotent stem cells Ub-specific processing proteases RUNX2 regulates bone development RUNX3 regulates CDKN1A transcription RUNX3 regulates BCL2L11 (BIM) transcription FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes FOXO-mediated transcription of cell cycle genes FOXO-mediated transcription of cell cycle genes		Colorectal cancer Hereditary hemorrhagic telangiectasia (HHT) Pancreatic cancer Juvenile polyposis syndrome
BRAF	B-Raf proto-oncogene, serine/threonine kinase	Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
MAP2K1	mitogen-activated protein kinase kinase 1	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants	K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide PD-0325901 N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
RAF1	Raf-1 proto-oncogene, serine/threonine kinase	Stimuli-sensing channels Rap1 signalling GP1b-IX-V activation signalling CD209 (DC-SIGN) signaling RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	Sorafenib LErafAON XL281 iCo-007 Cholecystokinin Regorafenib Dabrafenib Fostamatinib
RAP1B	RAP1B, member of RAS oncogene family	Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Rap1 signalling MAP2K and MAPK activation Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF MET activates RAP1 and RAC1 Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation Signaling downstream of RAS mutants Signaling by RAF1 mutants
MAPK8	mitogen-activated protein kinase 8	Activation of BIM and translocation to mitochondria Activation of BMF and translocation to mitochondria NRAGE signals death through JNK NRAGE signals death through JNK NRIF signals cell death from the nucleus Oxidative Stress Induced Senescence FCERI mediated MAPK activation DSCAM interactions JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Activation of the AP-1 family of transcription factors Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-38 signaling WNT5:FZD7-mediated leishmania damping	Tamoxifen Minocycline Pyrazolanthrone 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide Halicin
MTOR	mechanistic target of rapamycin kinase	PIP3 activates AKT signaling Macroautophagy MTOR signalling mTORC1-mediated signalling HSF1-dependent transactivation Energy dependent regulation of mTOR by LKB1-AMPK CD28 dependent PI3K/Akt signaling VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of PTEN gene transcription Amino acids regulate mTORC1	Pimecrolimus Sirolimus Everolimus Rimiducid SF1126 XL765 Ridaforolimus Temsirolimus Fostamatinib
PIK3CD	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	PIP3 activates AKT signaling Synthesis of PIPs at the plasma membrane Constitutive Signaling by Aberrant PI3K in Cancer Interleukin-3, Interleukin-5 and GM-CSF signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RET signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Caffeine XL765 TG100-115 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE Idelalisib Duvelisib Fostamatinib Copanlisib
GRIN1	glutamate ionotropic receptor NMDA type subunit 1	EPHB-mediated forward signaling EPHB-mediated forward signaling Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Glutamic acid Tramadol Enflurane Atomoxetine Pentobarbital Methadone Secobarbital Meperidine Acamprosate Donepezil Guaifenesin Memantine Memantine Orphenadrine Phenobarbital Aripiprazole Prasterone 5,7-Dichlorokynurenic acid D-Serine Cycloleucine Milnacipran CNS-5161 Acetylcysteine Ketobemidone Gavestinel Agmatine Ifenprodil Magnesium acetate tetrahydrate Magnesium carbonate Esketamine Fluciclovine (18F)
IRAK2	interleukin 1 receptor associated kinase 2	MyD88:MAL(TIRAP) cascade initiated on plasma membrane NOD1/2 Signaling Pathway TAK1 activates NFkB by phosphorylation and activation of IKKs complex activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Interleukin-1 signaling IRAK2 mediated activation of TAK1 complex TRAF6-mediated induction of TAK1 complex within TLR4 complex TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 dependent cascade initiated on endosome IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation MyD88 cascade initiated on plasma membrane
APBB1IP	amyloid beta precursor protein binding family B member 1 interacting protein	Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants
ARAF	A-Raf proto-oncogene, serine/threonine kinase	RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	ATP	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D	Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Glutamic acid Tramadol Enflurane Atomoxetine Pentobarbital Methadone Secobarbital Meperidine Acamprosate Donepezil Guaifenesin Memantine Orphenadrine Phenobarbital Aripiprazole Tenocyclidine Prasterone Milnacipran Acetylcysteine Ketobemidone Gavestinel Magnesium acetate tetrahydrate Magnesium carbonate Esketamine Fluciclovine (18F)
TLR2	toll like receptor 2	ER-Phagosome pathway Beta defensins MyD88:MAL(TIRAP) cascade initiated on plasma membrane Toll Like Receptor TLR1:TLR2 Cascade Toll Like Receptor TLR6:TLR2 Cascade MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) Regulation of TLR by endogenous ligand Neutrophil degranulation Modulation by Mtb of host immune system	Lyme disease vaccine (recombinant OspA) Adapalene S-(Dimethylarsenic)Cysteine Golotimod Tuberculin purified protein derivative
CDC25A	cell division cycle 25A	Transcription of E2F targets under negative control by DREAM complex Polo-like kinase mediated events Activation of ATR in response to replication stress Ub-specific processing proteases Cyclin E associated events during G1/S transition Cyclin A/B1/B2 associated events during G2/M transition Ubiquitin Mediated Degradation of Phosphorylated Cdc25A Cyclin A:Cdk2-associated events at S phase entry Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
CAV1	caveolin 1	Triglyceride catabolism eNOS activation NOSTRIN mediated eNOS trafficking Basigin interactions Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Extra-nuclear estrogen signaling FOXO-mediated transcription of cell cycle genes		Congenital generalized lipodystrophy (CGL)
CDC25C	cell division cycle 25C	Polo-like kinase mediated events Activation of ATR in response to replication stress RHO GTPases activate PKNs TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain Cyclin A/B1/B2 associated events during G2/M transition Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
CDH1	cadherin 1	Degradation of the extracellular matrix Degradation of the extracellular matrix Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Apoptotic cleavage of cell adhesion proteins Adherens junctions interactions RHO GTPases activate IQGAPs InlA-mediated entry of Listeria monocytogenes into host cells		Gastric cancer Penile cancer Nasopharyngeal cancer Breast cancer Hepatocellular carcinoma Thyroid cancer
PDGFB	platelet derived growth factor subunit B	Platelet degranulation PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer Non-integrin membrane-ECM interactions RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Pegpleranib	Malignant pleural mesothelioma Glioma
ITSN1	intersectin 1	NRAGE signals death through JNK Rho GTPase cycle EPHB-mediated forward signaling EPHB-mediated forward signaling G alpha (12/13) signalling events Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis

Search Results for: HRAS